Eloxx Pharmaceuticals (ELOX) director Nina S. Kjellson files initial Form 3

Rhea-AI Filing Summary

Eloxx Pharmaceuticals director files initial ownership report

Eloxx Pharmaceuticals, Inc. director Nina S. Kjellson has filed a Form 3, which is an initial statement of beneficial ownership for insiders. This filing does not list any stock or option transactions and serves mainly to register her insider status with regulators.

Key Terms

Form 3, initial statement of beneficial ownership, insider

3 terms

Form 3 regulatory

"has filed a Form 3, which is an initial statement of beneficial ownership"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

initial statement of beneficial ownership regulatory

"Form 3, which is an initial statement of beneficial ownership for insiders"

An initial statement of beneficial ownership is the first regulatory filing an insider or large investor submits to disclose the amount of a company's stock they control or benefit from. It matters to investors because it reveals who has significant influence over a company—like showing who’s holding the cards—and helps track potential conflicts of interest, insider motives, and future buying or selling that can move the stock price.

insider financial

"serves mainly to register her insider status with regulators"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kjellson Nina S

(Last) (First) (Middle)

C/O ELOXX PHARMACEUTICALS, INC.

P.O. BOX 274

(Street)

ARLINGTON MASSACHUSETTS 02476

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/27/2026

3. Issuer Name and Ticker or Trading Symbol
Eloxx Pharmaceuticals, Inc. [ ELOX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24, Power of Attorney, is attached.

No securities are beneficially owned.

	/s/ Sumit Aggarwal, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Eloxx Pharmaceuticals (ELOX) Form 3 for Nina S. Kjellson show?

The Form 3 for Eloxx Pharmaceuticals director Nina S. Kjellson reports her initial insider status. It does not disclose any stock or option transactions and functions as a regulatory baseline for future ownership and trading disclosures.

Did Nina S. Kjellson buy or sell Eloxx Pharmaceuticals (ELOX) shares in this Form 3?

No, this Form 3 does not report any share purchases, sales, or option exercises. It is purely an initial beneficial ownership filing, setting up future reporting of any transactions Nina S. Kjellson may make as a company director.

Why is a Form 3 filing important for Eloxx Pharmaceuticals (ELOX) investors?

Form 3 establishes the baseline disclosure for an insider’s holdings at Eloxx Pharmaceuticals. While it shows no transactions itself, it triggers ongoing reporting duties, so any future trades by director Nina S. Kjellson must be reported on subsequent forms like Form 4.

Does the Eloxx Pharmaceuticals (ELOX) Form 3 reveal any derivative positions?

No, the Form 3 summary shows no derivative transactions or remaining derivative positions for Nina S. Kjellson. The filing’s derivative-related fields are empty, indicating no options, warrants, or similar instruments are reported in this initial ownership statement.

Is there any indication of a trading plan in this Eloxx Pharmaceuticals (ELOX) Form 3?

There is no indication of trading plans or pre-arranged sales in this Form 3. The filing reports no transactions, and the available footnote section does not provide details suggesting a Rule 10b5-1 plan or similar arrangements.